In the current study, we use the same set of non-invasive tests to compare GBA1 carriers to participants with no genetic predisposition to PD in order to highlight potential differences and frequencies of prodromal features between both groups and possibly identify those individuals with a higher rate of PD-related prodromal features that would render these individuals eligible for future prevention studies. This evidence concerns the gene GBA1 and Parkinson disease.